Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumours|Breast Cancer|Head and Neck Cancer|Cervix Cancer|Prostate Cancer
Interventions: DRUG: Durvalumab + Tremelimumab + metronomic Vinorelbine
Sponsor: UNICANCER
Collaborators: National Cancer Institute, France|AstraZeneca|Pierre Fabre Laboratories